Article
Respiratory System
Florian Eichhorn, Hauke Winter
Summary: Patients with oligometastatic lung cancer, defined as having limited metastatic disease, may have better prognosis when treated with local ablative therapy for all lesions. In such cases, surgery and radiotherapy play a dominant role in the treatment course, offering a potentially curative local therapy in combination with systemic treatment based on interdisciplinary decisions.
EUROPEAN RESPIRATORY REVIEW
(2021)
Article
Oncology
Tian-Qi Du, Xiang Li, Wei-Si Zhong, Jian-Dong Tian, Yu-Xia Zhao, Dan Liu
Summary: For patients with brain metastasis of lung cancer, SIB-IMRT may be associated with a more favorable prognosis.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Review
Oncology
Georgios Tsakonas, Simon Ekman, Andreas Koulouris, Helen Adderley, Christoph Jakob Ackermann, Raffaele Califano
Summary: The presence of brain metastases is a negative prognostic factor for advanced nonsmall cell lung cancer patients. Targeted treatments have shown significant efficacy for brain metastases but are only applicable to a minority of patients. Systemic therapies for nononcogenic-driven NSCLC with brain metastases have limited clinical benefit.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Sumin Geng, Shaohua Tu, Zhenwei Bai, Yixiong Geng
Summary: Brain metastasis of lung cancer is a severe complication that affects patient survival. This study found that high-metastatic lung cancer cells have a higher capacity to pass through the blood-brain barrier (BBB) compared to low-metastatic cells. Brain microvascular endothelial cells can internalize exosomes derived from metastatic cells, promoting the passage of non-metastatic cells across the BBB. The upregulated exosomal long noncoding RNA (lncRNA) LINC01356 derived from metastatic cells plays a key role in remodeling the BBB system and participating in brain metastasis in lung cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Minmin Li, Yanbo Song, Longhao Li, Jian Qin, Hongbin Deng, Tao Zhang
Summary: The case report presented a patient with multiple BMs of NSCLC, who received two courses of WBRT and one course of GK radiotherapy over 5 years. The patient survived for 12 years with good tumor response to each radiotherapy, maintaining a high quality of life throughout the survival period.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Yu-Jung Lin, Yu-Mei Kang, Yuan-Hung Wu, Yi-Wei Chen, Yu-Wen Hu
Summary: WBRT can decrease lymphocyte counts and the magnitude of treatment-related lymphopenia is an independent predictor of survival in small-cell lung cancer patients. Male sex and higher baseline lymphocyte count are associated with a lower risk of developing treatment-related lymphopenia. Age at brain metastasis, grade 2 or higher treatment-related lymphopenia, and percentage change in lymphocyte count are prognostic factors of survival.
Article
Oncology
Ji Zhang, Juebin Jin, Yao Ai, Kecheng Zhu, Chengjian Xiao, Congying Xie, Xiance Jin
Summary: This study developed a radiomics nomogram to predict the survival of brain metastasis patients from non-small cell lung cancer who underwent whole brain radiotherapy, based on CT images and clinical factors. The nomogram showed good performance in predicting short-term and long-term survival, with high concordance index and area under curve.
FRONTIERS IN ONCOLOGY
(2021)
Review
Cell Biology
Bin Wang, Hanfei Guo, Haiyang Xu, Hongquan Yu, Yong Chen, Gang Zhao
Summary: CNS metastasis in NSCLC is a common complication that seriously affects patients' quality of life, and current treatment methods do not meet patients' needs, with many issues still needing to be addressed.
Article
Medicine, General & Internal
Mariano Provencio, Ernest Nadal, Jose L. Gonzalez-Larriba, Alex Martinez-Marti, Reyes Bernabe, Joaquim Bosch-Barrera, Joaquin Casal-Rubio, Virginia Calvo, Amelia Insa, Santiago Ponce, Noemi Reguart, Javier de Castro, Joaquin Mosquera, Manuel Cobo, Andres Aguilar, Guillermo Lopez Vivanco, Carlos Camps, Rafael Lopez-Castro, Teresa Moran, Isidoro Barneto, Delvys Rodriguez-Abreu, Roberto Serna-Blasco, Raquel Benitez, Carlos Aguado de la Rosa, Ramon Palmero, Florentino Hernando-Trancho, Javier Martin-Lopez, Alberto Cruz-Bermudez, Bartomeu Massuti, Atocha Romero
Summary: This study evaluated the efficacy of the neoadjuvant nivolumab plus chemotherapy regimen on operable stage III non-small-cell lung cancer (NSCLC) patients. The results showed that patients receiving the combination therapy had a higher rate of pathological complete response and longer survival, indicating the effectiveness of this treatment approach in this patient population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Medical Laboratory Technology
Lea Sinoquet, William Jacot, Xavier Quantin, Catherine Alix-Panabieres
Summary: This study discusses the application of immune checkpoint inhibitors in the treatment of metastatic nonsmall cell lung cancer and focuses on the evaluation of blood biomarkers such as circulating cell-free DNA, circulating tumor DNA, blood tumor mutational burden, and circulating tumor cells. Monitoring these biomarkers during immunotherapy may assist clinicians in making therapeutic decisions.
CLINICAL CHEMISTRY
(2023)
Article
Cell Biology
Baihua Yang, Wei Zhang, Jianjian Qiu, Yilin Yu, Jiancheng Li, Buhong Zheng
Summary: This research aimed to develop a brain metastasis (BM) model for limited-stage small cell lung cancer (LS-SCLC) patients and to assist in early identification of high-risk patients and personalized therapy selection. Univariate and multivariate logistic regression were used to identify independent risk factors of BM. A nomogram and receiver operating curve (ROC) were constructed based on these risk factors. The results showed that the nomogram model had high reliability and clinical applicability.
Article
Oncology
Zhengfei Zhu, Jianjiao Ni, Xuwei Cai, Shengfa Su, Hongqing Zhuang, Zhenzhou Yang, Ming Chen, Shenglin Ma, Conghua Xie, Yaping Xu, Jiancheng Li, Hong Ge, Anwen Liu, Lujun Zhao, Chuangzhou Rao, Congying Xie, Nan Bi, Zhouguang Hui, Guangying Zhu, Zhiyong Yuan, Jun Wang, Lina Zhao, Wei Zhou, Chai Hong Rim, Arturo Navarro-Martin, Ben G. L. Vanneste, Dirk De Ruysscher, J. Isabelle Choi, Jacek Jassem, Joe Y. Chang, Lucyna Kepka, Lukas Kasmann, Michael T. Milano, Paul Van Houtte, Rafal Suwinski, Alberto Traverso, Hiroshi Doi, Yang-Gun Suh, Georges Noel, Natsuo Tomita, Roman O. Kowalchuk, Terence T. Sio, Baosheng Li, Bing Lu, Xiaolong Fu
Summary: Timely radiotherapy can provide rapid symptom relief and enable subsequent aggressive treatments in patients with heavy tumor burden or oncologic emergencies. By incorporating radiotherapy appropriately as concurrent, consolidation, or salvage therapy, long-term survival or even cure can be achieved for patients with oligo-metastatic disease.
TRANSLATIONAL LUNG CANCER RESEARCH
(2022)
Article
Oncology
Yang Zhao, Shuyan Li, Xi Yang, Li Chu, Shengping Wang, Tong Tong, Xiao Chu, Fan Yu, Ya Zeng, Tiantian Guo, Yue Zhou, Liqing Zou, Yida Li, Jianjiao Ni, Zhengfei Zhu
Summary: In this study, osimertinib showed improved efficacy for brain metastasis in untreated EGFR-mutant NSCLC patients. Furthermore, upfront cranial local therapy, including stereotactic radiosurgery and/or surgery, was associated with additional survival benefit.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Biochemistry & Molecular Biology
Georgios Tsakonas, Andreas Koulouris, Dominika Kazmierczak, Johan Botling, Cristian Ortiz-Villalon, Helena Nord, Magnus Lindskog, Martin Sandelin, Patrick Micke, Per Hydbring, Simon Ekman
Summary: Spreading of tumor cells to the central nervous system is common in non-small cell lung cancer (NSCLC) and poses clinical challenges. We conducted microRNA profiling to identify differentially expressed microRNAs in brain metastases compared to primary NSCLC. We identified 11 microRNAs with differential expression, indicating their potential as biomarkers for brain metastasis in NSCLC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Respiratory System
Rudolf M. Huber, Diego Kauffmann-Guerrero, Hans Hoffmann, Michael Flentje
Summary: Recent developments in the treatment of locally advanced nonsmall cell lung cancer have focused on integrating immunotherapy with radiotherapy, chemotherapy, and adjuvant targeted therapy. The importance of consolidation therapy, pathological evaluation, and investigation of immunological features and driver mutations in improving management and prognosis has been emphasized.
EUROPEAN RESPIRATORY REVIEW
(2021)